Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Peringkat dalam Saham #18279
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Harga Saham
$1.79
Terakhir disinkronkan: 2026-09-02
Kapitalisasi Pasar
$205.75M
Perubahan (1 hari)
3.18%
Perubahan (1 tahun)
-61.61%
Negara
US
Perdagangan NovaBridge Biosciences (NBP)

Kategori

Riwayat pemecahan saham untuk NovaBridge Biosciences (NBP)
Saham NovaBridge Biosciences (simbol: NBP) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Sep 03, 2026.
Satu lembar saham NBP yang dibeli sebelum Sep 03, 2026 sekarang setara dengan 0 lembar saham NBP.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH